A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Sculier, J.
Lafitte, J.
Lecomte, J.
Alexopoulos, C.
Van Cutsem, O.
Giner, V.
Efremidis, A.
Scherpereel, A.
Paesmans, M.
Berghmans, T.
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] CHU Calmette, Lille, France
[3] CHU Charleroi, Charleroi, Belgium
[4] Evangelismos Gen Hosp, Athens, Greece
[5] Clin Univ St Luc, Namur, Belgium
[6] Hosp Sagunto, Valence, France
[7] Hellen Canc Inst, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：367S / 367S
页数：1
相关论文
共 50 条
  • [21] Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: A phase II trial
    Gatzemeier, U
    Heckmayer, M
    Neuhauss, R
    Schluter, I
    vonPawel, J
    Wagner, H
    Dreps, A
    SEMINARS IN ONCOLOGY, 1995, 22 (06) : 24 - 28
  • [22] Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Park, Keunchil
    Lin, Chia-Chi
    Huang, Dennis Chin-Lun
    Shin, Heather Hye-Jung
    Bogenrieder, Thomas
    Tan, Daniel S. -W.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S554 - S555
  • [23] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [25] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC)
    Tan, D.
    Lin, C. -C.
    Huang, D. Chin-Lun
    Jung, H.
    Bogenrieder, T.
    Park, K.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [27] Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
    Soussi, Ghassen
    Racil, Hajer
    Bacha, Saoussen
    Rouhou, Sana Cheikh
    Zidi, Asma
    Ayadi, Aida
    Chaouch, Nawel
    Chabbou, Abdellatif
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [28] Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)
    Reck, M
    ANTICANCER RESEARCH, 2005, 25 (3A) : 1501 - 1506
  • [29] Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Nagasaka, M.
    Goto, K.
    Gomez, J.
    Hida, T.
    Shu, C.
    Lee, C. K.
    Park, K.
    Cho, B. C.
    Lee, J.
    Ou, S.
    Bestvina, C.
    Natale, R.
    Haddish-Berhane, N.
    Bhattacharya, A.
    Verheijen, R.
    Agrawal, T.
    Knoblauch, R.
    Govindan, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1116 - S1116
  • [30] Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Bonanno, Laura
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (03) : 160 - 171
12345